Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest HAL Allergy B.V. Stories

2012-12-19 04:20:40

LEIDEN - The Netherlands, December 19, 2012 /PRNewswire/ -- HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II trial with SUBLIVAC(R) FIX Phleum pratense. This combined dose tolerability and dose range finding study will characterize the dose-response relationship of SUBLIVAC(R) FIX Phleum pratense in order to support the optimal dose in terms of clinical efficacy and safety for further investigation in Phase III studies....

2012-11-06 12:27:00

LEIDEN, Netherlands, November 6, 2012 /PRNewswire/ -- HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II trial with SUBLIVAC(R) FIX Birch. This combined dose tolerability and dose range finding study will characterize the dose-response relationship of SUBLIVAC(R) FIX Birch in order to support the optimal dose in terms of clinical efficacy and safety. The multi-centre, randomized, double-blind, placebo-controlled study in...

2012-10-23 11:24:44

LEIDEN, The Netherlands, October 23, 2012 /PRNewswire/ -- HAL Allergy B.V. today introduces its Scientific Advisory Board. This group of specialists will advise and assist the company in order to realize its future plans. The successful kick-off meeting took place on October 6th in Leiden. The introduction of the Scientific Advisory Board is an important step in the further development of the organization. In 2011 HAL Allergy started an ambitious clinical development...

2012-07-05 22:20:20

LEIDEN, The Netherlands, July 6, 2012 /PRNewswire/ -- HAL Allergy B.V. announced that it succeeded in extending its GMP contract manufacturing activities for clinical batch supply of both recombinant and viral products. The Dutch inspectorate granted the permit extension after inspection of the operational activities in the BSL2 clean rooms and development laboratory in June 2012. In 2009 HAL Allergy opened its state-of-the-art production facility at the Bio Science Park...

2012-03-20 06:26:39

LEIDEN, The Netherlands, March 20, 2012 /PRNewswire/ -- HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II dose range finding study. This multi-centre, randomized, double-blind, placebo-controlled study in 250 patients with persistent allergic rhinitis / rhinoconjunctivitis will characterize the dose-response relationship of PURETHAL(R) Mites in order to support the optimal dose in terms of clinical efficacy and safety....

2011-10-31 03:05:00

LEIDEN, the Netherlands, October 31, 2011 /PRNewswire/ -- HAL Allergy B.V. today announced that it has included the first patient in its PHASE II dose range finding study. This multi-centre, randomized, double-blind, placebo-controlled study in patients with persistent allergic rhinitis/rhinoconjunctivitis will characterize the dose-response relationship of PURETHAL(R) Mites in order to support the optimal dose in terms of clinical efficacy and safety. The study has been...